Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5363
Name myxoid liposarcoma
Definition A liposarcoma that is characterized by the presence of a hypocellular spindle cell proliferation set in a myxoid background and has_material_basis_in chromosomal translocations.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma myxoid liposarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp Dovitinib myxoid liposarcoma sensitive detail...
FGFR2 amp Dovitinib + Trabectedin myxoid liposarcoma sensitive detail...
FGFR2 amp PD173074 myxoid liposarcoma sensitive detail...
FGFR2 amp Infigratinib myxoid liposarcoma sensitive detail...
FGFR2 amp PD173074 + Trabectedin myxoid liposarcoma sensitive detail...
FGFR2 amp Infigratinib + Trabectedin myxoid liposarcoma sensitive detail...
PIK3CA H1047R Copanlisib myxoid liposarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01506596 Phase II Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02609984 Phase II Atezolizumab G305 + ID-LV305 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Terminated USA 0
NCT02992743 Phase II NY-ESO-1-c259T A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Completed USA 0
NCT03450122 Phase I Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 Aldesleukin + Cyclophosphamide Aldesleukin + Cyclophosphamide + ID-LV305 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Completed USA 0
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Active, not recruiting USA 0
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting USA 0
NCT04044768 Phase II ADP-A2M4 cells Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting USA | GBR | FRA | ESP | CAN 0
NCT04526509 Phase I Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors Active, not recruiting USA | DEU | CAN | AUS 2
NCT04794127 Phase II Pioglitazone + Trabectedin Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (TRABEPIO) Recruiting ITA 0
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Completed USA 0
NCT05043649 Phase I Camsirubicin + Pegfilgrastim Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Recruiting USA 0
NCT05120271 Phase Ib/II BOXR1030 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) Recruiting USA 0
NCT05809830 Phase Ib/II Doxorubicin Doxorubicin + LB-100 Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) Recruiting ESP 0
NCT06083883 Phase I Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 Not yet recruiting USA 0
NCT06217536 Phase Ib/II Lurbinectedin Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Not yet recruiting USA 0